Study details
Enrolling now
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT IDNCT06205836ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
33
Study length
about 4 years
Ages
18+
Locations
1 site in MD
About this study
Researchers are testing the safety and effectiveness of cemiplimab, either alone or with fianlimab, in older adults (70+) diagnosed with localized or locally advanced microsatellite unstable colorectal cancer. The trial will last for approximately 1448 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cemiplimab
- 2.Take Fianlimab
PhasePhase 2
DrugCemiplimab
Primary goalComplete Response Rate
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
cemiplimab
Endpoints
Primary: Complete Response Rate
Body systems
Oncology